Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present QIAGEN N.V. (NYSE: QGEN).

Full DD Report for QGEN

You must become a subscriber to view this report.


Recent News from (NYSE: QGEN)

Qiagen teams up with NeoGenomics in companion diagnostics
QIAGEN (NASDAQ: QGEN ) and NeoGenomics (NASDAQ: NEO ) ink a collaboration agreement aimed at accelerating the availability of companion diagnostic tests for new cancer therapies. Their goal is to have the tests available on the first day of patient access to newly approved cancer drugs. ...
Source: SeekingAlpha
Date: November, 30 2018 16:20
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics tha...
Source: Business Wire
Date: November, 30 2018 16:04
QIAGEN launches QCI Interpret bioinformatics features for use for blood cancers as well as a novel myeloid gene panel for GeneReader NGS System
Highlighting Sample to Insight solutions for next-generation sequencing at American Society of Hematology 2018 meeting QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a...
Source: Business Wire
Date: November, 29 2018 16:00
Eyes On Cyber Monday, Argentina And Mars (Stocks To Watch Podcast)
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f...
Source: SeekingAlpha
Date: November, 25 2018 08:08
QIAGEN NV (QGEN) Q3 2018 Results - Earnings Call Transcript
QIAGEN NV (QGEN) Q3 2018 Earnings Call October 30, 2018 9:00 am ET Executives John Gilardi - QIAGEN NV Peer Michael Schatz - QIAGEN NV Roland Sackers - QIAGEN NV Analysts Patrick Donnelly - Goldman Sachs & Co. LLC Tycho W. Peterson - JPMorgan Securities LLC Luke Ser...
Source: SeekingAlpha
Date: October, 30 2018 17:17
Qiagen Q3 sales up 4%; earnings up 24%; earnings guidance raised
QIAGEN N.V. (NASDAQ: QGEN ) Q3 results ($M): Sales: 377.9 (+3.8%). More news on: Qiagen N.V., Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: October, 29 2018 16:40
Qiagen beats by $0.02, misses on revenue
Qiagen (NASDAQ: QGEN ): Q3 Non-GAAP EPS of $0.35 beats by $0.02 ; GAAP EPS of $0.26 beats by $0.04 . More news on: Qiagen N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 29 2018 16:10
QIAGEN Expands QIAGEN Clinical Insight Software to Support All Major Sequencing Platforms and Assay Types
Adding QCI Analyze Universal to NGS bioinformatics offering, plus immuno-oncology content and additional features in analysis and interpretation QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of major enhancements to QIAGEN Clinical Insight (QCI) bi...
Source: Business Wire
Date: October, 29 2018 16:05
QIAGEN Reports Results for Third Quarter and First Nine Months of 2018
Q3 2018 results exceed targets as QIAGEN on track to achieve 2018 goals: Net sales of $377.9 million +3.8% reported (+6.5% at constant exchange rates, or CER vs. ~6% CER guidance) EPS of $0.26; adjusted EPS $0.35 ($0.36 CER vs. ~$0.33-0.34 CER guidance) Free cash flow fo...
Source: Business Wire
Date: October, 29 2018 16:05
QIAGEN Expands Next-Generation Sequencing Portfolio with Oncology and Immuno-Oncology Panels for Research Using GeneReader NGS System and Other Platforms
Sample to Insight solutions enabling deep analysis of disease-related genomic mutations QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three innovative Sample to Insight workflows for next-generation sequencing (NGS) research in oncology using QI...
Source: Business Wire
Date: October, 29 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1437.9638.2338.2937.94808,536
2018-08-2338.8338.9139.0138.73445,790
2018-08-2239.0239.3039.3438.791,427,703
2018-08-2138.2738.2438.4737.971,188,758
2018-08-2037.6337.7437.8237.551,169,875

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-124,3009,17446.8716Short
2018-12-112,4403,32073.4940Short
2018-12-101,9807,89025.0951Cover
2018-12-072,3605,64741.7921Short
2018-12-063,11613,35823.3268Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on QGEN.


About QIAGEN N.V. (NYSE: QGEN)

Logo for QIAGEN N.V. (NYSE: QGEN)

Not available

 

Contact Information

 

 

Current Management

  • Metin Colpan / CEO
  • Peer M. Schatz / CFO

Current Share Structure

  • Market Cap: $8,224,013,837 - 05/29/2018
  • Issue and Outstanding: 226,556,855 - 12/31/2017

 


Recent Filings from (NYSE: QGEN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 31 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 31 2018
Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 06 2018
Disclosure of dealings with Iran, such as contact with or support for Iran
Filing Type: IRANNOTICEFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 07 2018

 

 


Daily Technical Chart for (NYSE: QGEN)

Daily Technical Chart for (NYSE: QGEN)


Stay tuned for daily updates and more on (NYSE: QGEN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: QGEN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in QGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of QGEN and does not buy, sell, or trade any shares of QGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/